Stempeutics Research Bangalore is a late stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. It was incorporated by the Manipal Group in Jan 2006 and entered into a strategic alliance with Cipla in 2009. Stempeutics strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team.
Currently it is focussing on the following three innovative products: Stempeucel®, Stempeucare™ and Stempeutron™
In 2016 DCGI (Indian FDA) granted limited approval of Stempeucel® product sales for the treatment of CLI patients due to Buerger's disease. Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI for limited sales. Stempeutics has successfully put India on the global map for cutting edge drug discovery in the area of Stem Cells as Stempeucel® is one of the few stem cell products to be approved by a Regulatory body, anywhere in the world.